(Q35866092)

10 August 2017

1 reference

title

Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors (English)

1 reference

10 August 2017

main subject

venous thromboembolism

1 reference

Edith A Nutescu

1

1 reference

10 August 2017

Cathy M Helgason

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

24

1 reference

10 August 2017

issue

7 Pt 2

1 reference

10 August 2017

page(s)

82S-87S

1 reference

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Venous thrombosis: a multicausal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Antithrombotic therapy for venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

21 January 2018

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Direct thrombin inhibitors for anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Selective inhibition of coagulation factors: advances in antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

Secondary prophylaxis with warfarin for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.10.82S.36121

10.1592/PHCO.24.10.82S.36121

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference